SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SomaLogic, Inc.

SomaLogic is fostering the discovery of effective and safer treatments for patients while empowering more accurate diagnosis, prevention, and treatment of disease through the next generation of proteomics.

SoftBank Capital

T. Rowe Price

Illumina

ARK Investment Management

Corvex

Counterpoint Global

Farallon Capital Management

Perceptive Advisors

Casdin Capital

Janus Henderson Investors

Ziff Capital Partners

Revelation Partners

Amgen

Boston Millennia Partners

Novartis

Redmile Group

Intermountain Ventures

Logos Capital

Millennium Management

SomaLogic

ICYMI ... Andra Krauze, MD, Physician Early Investigator and radiation oncologist at National Cancer Institute (NCI), presented how to effectively balance genomics, transcriptomics, and metabolomics, alongside proteomic platforms and clinical data, along with approaches for connecting proteomic data with the clinic. 

"Harnessing AI and proteomics for glioblastoma"

Catch up on the research here ➡️  https://lnkd.in/gnG4k5ex

#glioblastoma #biomarkerdiscovery #biomarkers 

How are academic, industry and government partners driving the precision neuroscience revolution, both as individual contributors and within the Global Neurodegeneration Proteomics Consortium?  

Now available! Chris Whelan, PhD, Carlos Cruchaga, PhD, and Keenan Walker, PhD, discuss their work measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.  
 
Access the on-demand webinar ➡️ https://bit.ly/3SdOT8r  
 
#Alzheimers # neuroscience #proteomics #biomarkers 

Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on using the NASH bundle of SomaSignal® Tests in a recently completed trial.

🎥 Watch today: Correlation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes

#proteomics #biomarkers #drugdiscovery 

Catching up on research this week? Watch Ali Javaheri, MD, present findings from proteomics-based studies that identified ApoM as a mediator of risk in diabetes, heart failure, and chemotherapeutic cardiotoxicity, as well as the association between ApoM and heart failure outcomes, which has been validated in multiple cohorts using the SomaScan® Assay.

#proteomics #biomarkers #drugdiscovery 

Thank you to all the authors who have published discoveries they’ve made using the SomaScan® Assay. Each new study advances precision medicine worldwide – and inspires us to keep innovating.  
 
📖 Look through all their peer-reviewed research here: https://bit.ly/3RnkGSh 

Narrow your search by keyword. Or filter by date, and catch up on what’s new. 
 
#proteomics #biomarkers #drugdiscovery #drugdevelopment #aptamers 

	Dec '19	Dec '20	Dec '21	Dec '22
account payables	3.02M -	7.06M 133.91%	15.09M 113.60%	16.79M 11.30%
accumulated other comprehensive income loss		-2K -	-72K 3,500%	-513K 612.50%
cash and cash equivalents	14.06M -	164.94M 1,073.14%	439.49M 166.45%	421.83M 4.02%
cash and short term investments	45.55M -	204.90M 349.78%	657.71M 220.99%	539.59M 17.96%
common stock	727K -	11K 98.49%	18K 63.64%	19K 5.56%
deferred revenue		1.76M -	3.02M 71.45%	3.38M 11.98%
deferred revenue non current		3.42M -	2.36M 30.78%	31.73M 1,242.30%
deferrred tax liabilities non current
goodwill				10.40M -
goodwill and intangible assets				27.10M -
intangible assets				16.70M -
inventory	8.43M -	7.02M 16.73%	11.21M 59.73%	13.90M 23.94%
long term debt	36.57M -	34.25M 6.33%
long term investments
net debt	-14.06M -	-128.27M 812.30%	-439.49M 242.63%	-419.35M 4.58%
net receivables	4.20M -	17.45M 315.16%	17.07M 2.15%	17.01M 0.40%
other assets	5.79M -
other current assets	1.58M -	1.16M 26.66%	5.10M 340.16%	9.87M 93.70%
other current liabilities	5.88M -	6.55M 11.28%	11.18M 70.66%	20.68M 85.04%
other liabilities	5.37M -
other non current assets	-5.71M -	6.40M 212.18%	4.99M 22.01%	19.01M 280.73%
other non current liabilities	-36.57M -	909K 102.49%	62.43M 6,767.88%	9.75M 84.38%
othertotal stockholders equity	378.04M -	597.27M 57.99%	1.11B 86.01%	1.17B 5.41%
preferred stock
property plant equipment net	5.71M -	3.91M 31.44%	9.56M 144.24%	19.56M 104.71%
retained earnings	-358.35M -	-411.37M 14.79%	-498.91M 21.28%	-608.07M 21.88%
short term debt		2.42M -		2.48M -
short term investments	31.50M -	39.95M 26.86%	218.22M 446.17%	117.76M 46.04%
tax assets
tax payables
total assets	71.26M -	242.29M 240.00%	706.10M 191.43%	647.37M 8.32%
total current assets	59.77M -	231.97M 288.13%	691.55M 198.11%	581.70M 15.88%
total current liabilities	8.90M -	17.80M 99.88%	29.29M 64.55%	43.33M 47.97%
total debt		36.67M -		2.48M -
total investments	31.50M -	39.95M 26.86%	218.22M 446.17%	117.76M 46.04%
total liabilities	50.84M -	56.37M 10.88%	94.08M 66.88%	84.82M 9.85%
total liabilities and stockholders equity		242.29M -	706.10M 191.43%	647.37M 8.32%
total non current assets	5.71M -	10.31M 80.74%	14.55M 41.06%	65.67M 351.36%
total non current liabilities	36.57M -	38.58M 5.49%	64.79M 67.96%	41.48M 35.97%
total stockholders equity	20.42M -	185.92M 810.47%	612.02M 229.19%	562.56M 8.08%

COM:SOMALOGIC

SomaLogic Inc

Last Close

2.29

05/01 21:00

Market Cap

396.23M

Beta: -

Volume Today

33.91M

Avg: -

Preview